Blastic plasmacytoid dendritic cell neoplasm: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
[[File:PMC4314974_OL-09-03-1388-g02.png|thumb]]<br>Blastic Plasmacytoid Dendritic Cell Neoplasm | {{SI}} | ||
{{Infobox medical condition | |||
| name = Blastic plasmacytoid dendritic cell neoplasm | |||
| image = [[File:PMC4314974_OL-09-03-1388-g02.png|250px]] | |||
| caption = Histopathological image of blastic plasmacytoid dendritic cell neoplasm | |||
| field = [[Hematology]] | |||
| symptoms = Skin lesions, fever, fatigue, lymphadenopathy | |||
| complications = [[Leukemia]], [[bone marrow failure]] | |||
| onset = Typically in adults, median age around 60 | |||
| duration = Chronic | |||
| causes = Unknown | |||
| risks = Possible genetic predisposition | |||
| diagnosis = [[Biopsy]], [[immunophenotyping]], [[flow cytometry]] | |||
| differential = [[Acute myeloid leukemia]], [[cutaneous T-cell lymphoma]] | |||
| treatment = [[Chemotherapy]], [[stem cell transplantation]] | |||
| prognosis = Poor, median survival less than 2 years | |||
| frequency = Rare | |||
}} | |||
[[File:PMC4314974_OL-09-03-1388-g02.png|left|thumb]]<br>Blastic Plasmacytoid Dendritic Cell Neoplasm | |||
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the proliferation of plasmacytoid dendritic cells. It primarily affects the skin, bone marrow, and lymph nodes. | Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the proliferation of plasmacytoid dendritic cells. It primarily affects the skin, bone marrow, and lymph nodes. | ||
==Clinical Presentation== | ==Clinical Presentation== | ||
Patients with BPDCN often present with skin lesions, which may appear as bruise-like patches, nodules, or plaques. These lesions are typically purple or red and can occur anywhere on the body. In addition to skin involvement, BPDCN can affect the bone marrow, leading to cytopenias, and the lymph nodes, causing lymphadenopathy. | Patients with BPDCN often present with skin lesions, which may appear as bruise-like patches, nodules, or plaques. These lesions are typically purple or red and can occur anywhere on the body. In addition to skin involvement, BPDCN can affect the bone marrow, leading to cytopenias, and the lymph nodes, causing lymphadenopathy. | ||
==Pathophysiology== | ==Pathophysiology== | ||
BPDCN arises from plasmacytoid dendritic cells, which are a type of immune cell involved in the production of interferon and the activation of other immune cells. The neoplastic cells in BPDCN express markers such as CD4, CD56, and CD123, which are used in the diagnosis of the disease. | BPDCN arises from plasmacytoid dendritic cells, which are a type of immune cell involved in the production of interferon and the activation of other immune cells. The neoplastic cells in BPDCN express markers such as CD4, CD56, and CD123, which are used in the diagnosis of the disease. | ||
==Diagnosis== | ==Diagnosis== | ||
The diagnosis of BPDCN is based on a combination of clinical presentation, histopathological examination, and immunophenotyping. Skin biopsies, bone marrow aspirates, and lymph node biopsies are commonly used to obtain tissue samples for analysis. Immunohistochemistry is employed to detect the characteristic markers of BPDCN. | The diagnosis of BPDCN is based on a combination of clinical presentation, histopathological examination, and immunophenotyping. Skin biopsies, bone marrow aspirates, and lymph node biopsies are commonly used to obtain tissue samples for analysis. Immunohistochemistry is employed to detect the characteristic markers of BPDCN. | ||
==Treatment== | ==Treatment== | ||
Treatment options for BPDCN include chemotherapy, targeted therapy, and hematopoietic stem cell transplantation. Traditional chemotherapy regimens used for acute leukemia may be employed, but newer targeted therapies, such as tagraxofusp, have shown promise in treating BPDCN. Allogeneic stem cell transplantation is considered in eligible patients to achieve long-term remission. | Treatment options for BPDCN include chemotherapy, targeted therapy, and hematopoietic stem cell transplantation. Traditional chemotherapy regimens used for acute leukemia may be employed, but newer targeted therapies, such as tagraxofusp, have shown promise in treating BPDCN. Allogeneic stem cell transplantation is considered in eligible patients to achieve long-term remission. | ||
==Prognosis== | ==Prognosis== | ||
The prognosis for BPDCN is generally poor due to its aggressive nature and high rate of relapse. Early diagnosis and treatment are crucial for improving outcomes. The development of targeted therapies has provided new hope for patients with this challenging disease. | The prognosis for BPDCN is generally poor due to its aggressive nature and high rate of relapse. Early diagnosis and treatment are crucial for improving outcomes. The development of targeted therapies has provided new hope for patients with this challenging disease. | ||
==See also== | |||
== | |||
* [[Hematologic malignancy]] | * [[Hematologic malignancy]] | ||
* [[Plasmacytoid dendritic cell]] | * [[Plasmacytoid dendritic cell]] | ||
| Line 30: | Line 35: | ||
* [[Immunophenotyping]] | * [[Immunophenotyping]] | ||
* [[Hematopoietic stem cell transplantation]] | * [[Hematopoietic stem cell transplantation]] | ||
{{Hematology}} | {{Hematology}} | ||
[[Category:Hematologic neoplasms]] | [[Category:Hematologic neoplasms]] | ||
[[Category:Rare diseases]] | [[Category:Rare diseases]] | ||
Latest revision as of 18:20, 4 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Blastic plasmacytoid dendritic cell neoplasm | |
|---|---|
| |
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Skin lesions, fever, fatigue, lymphadenopathy |
| Complications | Leukemia, bone marrow failure |
| Onset | Typically in adults, median age around 60 |
| Duration | Chronic |
| Types | N/A |
| Causes | Unknown |
| Risks | Possible genetic predisposition |
| Diagnosis | Biopsy, immunophenotyping, flow cytometry |
| Differential diagnosis | Acute myeloid leukemia, cutaneous T-cell lymphoma |
| Prevention | N/A |
| Treatment | Chemotherapy, stem cell transplantation |
| Medication | N/A |
| Prognosis | Poor, median survival less than 2 years |
| Frequency | Rare |
| Deaths | N/A |
Blastic Plasmacytoid Dendritic Cell Neoplasm
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the proliferation of plasmacytoid dendritic cells. It primarily affects the skin, bone marrow, and lymph nodes.
Clinical Presentation[edit]
Patients with BPDCN often present with skin lesions, which may appear as bruise-like patches, nodules, or plaques. These lesions are typically purple or red and can occur anywhere on the body. In addition to skin involvement, BPDCN can affect the bone marrow, leading to cytopenias, and the lymph nodes, causing lymphadenopathy.
Pathophysiology[edit]
BPDCN arises from plasmacytoid dendritic cells, which are a type of immune cell involved in the production of interferon and the activation of other immune cells. The neoplastic cells in BPDCN express markers such as CD4, CD56, and CD123, which are used in the diagnosis of the disease.
Diagnosis[edit]
The diagnosis of BPDCN is based on a combination of clinical presentation, histopathological examination, and immunophenotyping. Skin biopsies, bone marrow aspirates, and lymph node biopsies are commonly used to obtain tissue samples for analysis. Immunohistochemistry is employed to detect the characteristic markers of BPDCN.
Treatment[edit]
Treatment options for BPDCN include chemotherapy, targeted therapy, and hematopoietic stem cell transplantation. Traditional chemotherapy regimens used for acute leukemia may be employed, but newer targeted therapies, such as tagraxofusp, have shown promise in treating BPDCN. Allogeneic stem cell transplantation is considered in eligible patients to achieve long-term remission.
Prognosis[edit]
The prognosis for BPDCN is generally poor due to its aggressive nature and high rate of relapse. Early diagnosis and treatment are crucial for improving outcomes. The development of targeted therapies has provided new hope for patients with this challenging disease.
